Understanding Tagrisso Prescribing Information: Dosage, Indications and Contraindications
When it comes to prescribed medication, understanding the prescribing information is crucial to ensure proper use and avoid harmful interactions. Tagrisso is no exception. In this article, we’ll cover everything you need to know about Tagrisso prescribing information, from dosage to indications and contraindications.
Introduction:
Tagrisso, also known as osimertinib, is a prescription medication used to treat non-small cell lung cancer (NSCLC) that has specific mutations (EGFR T790M). By understanding its prescribing information, patients and health care providers can make informed decisions about whether Tagrisso is the right medication for them.
Dosage:
According to the prescribing information, the recommended dosage of Tagrisso is 80 mg taken orally once daily with or without food. The medication comes in tablet form, and it is essential to follow the dosage instructions carefully. It is not recommended to crush or chew the Tagrisso tablets.
Indications:
Tagrisso is indicated for patients with NSCLC with EGFR T790M mutation. It is important to note that Tagrisso is not effective for patients with NSCLC who do not have this mutation. Those patients should seek alternative treatments.
Contraindications:
Firstly, Tagrisso is contraindicated for patients with a known hypersensitivity to osimertinib. Secondly, patients with severe or intolerable adverse reactions such as interstitial lung disease, pneumonitis, or QTc interval prolongation should discontinue use immediately.
Suitable Subheadings:
– Dosage
– Indications
– Contraindications
Uses:
A clinical trial study with Tagrisso showed that patients who took Tagrisso had a median duration of response of 9.7 months, and 48 out of 63 patients saw an improvement in symptoms.
Examples/Case Studies:
A 2017 study in the New England Journal of Medicine showed that Tagrisso extended progression-free survival significantly without worsening patient quality of life. The study concluded that osimertinib “should be the new standard of care for patients with EGFR mutation-positive advanced NSCLC.”
Conclusion:
In conclusion, understanding Tagrisso prescribing information is essential to ensure proper use and avoid harmful interactions. It is important to take Tagrisso as prescribed at the recommended dosage of 80 mg taken orally once daily. It is also crucial to note that Tagrisso is contraindicated for patients with a known hypersensitivity to osimertinib or severe adverse reactions. Proper use of Tagrisso has been shown to improve symptoms and extend progression-free survival in certain patients with NSCLC.
